=>
Uploading C:\Program Files\Stnexp\Queries\10564185-rce.str



chain nodes :
10 11 12 13 15 16
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
8-10 10-11 11-12 11-13 13-15 15-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
5-6 5-7 6-9 7-8 8-9 8-10 10-11 11-12 11-13 13-15 15-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 15:CLASS 16:Atom
Generic attributes :
13:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic
16:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System : Monocyclic

Element Count :
Node 13: Limited
C,C6

Node 16: Limited
N,N1
C,C5

L1 STRUCTURE UPLOADED

=> d his

FILE 'REGISTRY' ENTERED AT 15:24:24 ON 28 JAN 2009
L1 STRUCTURE UPLOADED
L3 54 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:24:52 ON 28 JAN 2009
L4 1 S L3

=> d l4 bib abs

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:55062 CAPLUS Full-text
DN 142:134604

TI Preparation of benzimidazole amides as raf kinase inhibitors

IN Buchstaller, Hans-Peter; Finsinger, Dirk; Wiesner, Matthias; Burgdorf, Lars; Amendt, Christiane; Grell, Matthias; Sirrenberg, Christian; Zenke, Frank

PA Merck Patent GmbH, Germany

SO PCT Int. Appl., 145 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005004864	A1	20050120	WO 2004-EP6419	20040615
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004255403	A1	20050120	AU 2004-255403	20040615
	CA 2531859	A1	20050120	CA 2004-2531859	20040615
	EP 1653951	A1	20060510	EP 2004-739891	20040615
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	JP 2007513054	T	20070524	JP 2006-519783	20040615
	US 20070010560	A1	20070111	US 2006-564185	20060807
PRAI	EP 2003-15582	A	20030711		
	WO 2004-EP6419	W	20040615		

OS CASREACT 142:134604; MARPAT 142:134604

GI



I



II

AB Title compds. I [R6-7 = H, A, SO2A; A = alkyl, alkenyl, cycloalkyl, etc.; Ar2 = aromatic hydrocarbon; R8-10 = H, A, cycloalkyl, etc.; X = divalent alkyl, etc.; p, n = 0-5; q = 0-4] are prepared For instance, II is prepared from the corresponding 2-aminoimidazole and carboxylic acid (DMF, TBTU, HOBt, i-

Pr2NEt). I are raf kinase inhibitors and are useful for the treatment of cancer.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 15:25:39 ON 28 JAN 2009